Skip Navigation Links   >   Home   >   News & Media
01 December 2020

OCT Company Values: How We Pursue Our Mission and Vision

OCT Company Values: How We Pursue Our Mission and Vision

At Oxford Cannabinoid Technologies (OCT) our mission is to improve lives through the power of cannabinoids. Our vision is to be the best at turning cannabinoids into prescription medication to address the significant unmet medical needs of millions of patients around the world living with severe and chronic pain.

Our company values form the foundation of what we do at OCT, underpinning how we approach the pursuit of our mission and vision as a team. I know from my experience working as a coach, that to set a team up for success you need a strong values-based foundation. When the management team at OCT first came together we spent a good deal of time and energy building that foundation from scratch. Drug development can be a rocky road, pharmaceutical companies like ours face many challenges along the way, so we knew that it was important to have a solid base we could rely on.

As a company, the things we hold most dear are excellence, collaboration, respect, fairness and integrity. Let’s take these in turn, so I can explain why they are so important to us.

Excellence 

For us, this is an end and a means. Developing prescription medications does not happen overnight – it’s a long game. We want to make sure that we remember the journey as well as the destination. So, we make sure to celebrate successes along the way. The pursuit of excellence drives us to care deeply about our company’s mission and the patients that we are ultimately hoping to help. It underpins our commitment to rigorous research and our attention to detail, as we work to develop life-changing treatments for the patients most in need.

Collaboration

We all know the old saying: If you want to go fast, go alone. If you want to go far, go together. We want to go far and, if you ask John Lucas, he’ll tell you we’d like to get there as fast as possible.

The successful outcomes of our research depend upon collaboration. As a tight-knit team, we strive to always be supportive of each other. We are generous with our time, care and expertise. This has created a highly collegiate culture in which we are happy to learn from our mistakes. We recognise that we are better together. This approach extends beyond OCT to our work with external partners who we approach with the same principle of collaboration. It’s this focus on collaboration that has helped us to work seamlessly alongside prestigious academic institutions, such as Oxford University, and to partner with top-tier research organisations.

Respect

Regardless of whether we collaborate as a team or with external partners, we demonstrate high regard for everyone: each other, our stakeholders, and the wider community. By making respect a cornerstone, we empower people to speak up, to take risks and to be vulnerable. Having a respectful workplace culture promotes conversation, encourages people to ask questions, and makes for better outcomes overall.

Fairness

We value authenticity. We don’t want to work with your ‘representative’, we want the real you. We listen to each other and we are prepared to evolve together. Our company is free from discrimination and dishonesty and we treat each other with dignity. We look out for each other’s health and wellbeing. We recognise that people who are valued and nurtured do great work.

Integrity

As a team we are committed to doing the right thing, even when no one is watching. We make sure colleagues and external partners can rely on us: we keep our promises. When something goes wrong, we put our hands up and work together to resolve the issue.

 

This has been a challenging year for everyone and on so many fronts. One of the things that has made a difference here at OCT has been having our values so clearly defined. With such a strong foundation, it’s been easier to ride the 2020 rollercoaster.

As we prepare for the year ahead, we know that those values will continue to support us as we work to fulfil our mission, whatever the future might hold.

 

Author: Clarissa Sowemimo-Coker

    All News

    • Oxford Cannabinoid Technologies Holdings plc to conduct live presentations to retail investors

      04 June 2021 Live Presentation
    • OCT Forges Partnership with Voisin Consulting Life Sciences

      OCT Forges Partnership with Voisin Consulting Life Sciences

      01 June 2021 OCT Partnership
    • Oxford Cannabinoid Technologies Announces Changes to Executive Team

      11 January 2021 Oxford Cannabinoid Technologies Announces Changes to Executive Team
    • OCT Company Values: How We Pursue Our Mission and Vision

      OCT Company Values: How We Pursue Our Mission and Vision

      01 December 2020 OCT Company Values
    • OCT - Meet the Team Interview Series: Valentino Parravicini, Chief Scientific Officer

      Meet the Team Interview Series: Dr Valentino Parravicini, Chief Scientific Officer

      26 October 2020 Meet the Team Interview Series
    • OCT - A Pharmaceutical Company Focused on Developing Cannabinoids to Pain

      07 September 2020 OCT - A Pharmaceutical Company Focused on Developing Cannabinoids to Pain
    • OCT Appoints Dr Valentino Parravicini as Chief Scientific Officer as the business prepares for exciting new developments

      OCT Appoints Dr Valentino Parravicini as Chief Scientific Officer

      28 July 2020 OCT Press Release
    • Cannabinoids in medicine part 5: Treating COVID-19

      17 June 2020 Open Access Government
    • Why the Government should continue to invest in Life Sciences post COVID-19

      Why the government should continue to invest in Life Sciences post COVID-19

      01 June 2020 OCT blog - John Lucas, COO
    • OCT researchers publish new study examining genes involved in treating neuropathic pain

      19 April 2020 OCT Press Release
    • OCT announces pre-clinical development of new cannabinoid compound ‘OCT461201’ to treat IBS

      03 April 2020 OCT Press Release
    • Cannabinoids in medicine part 4: Epilepsy

      30 March 2020 Open Access Government
    • Cannabinoids in Medicine Part 3: Psoriasis and Rheumatoid Arthritis

      07 January 2020 Open Access Government
    • Cannabinoids in medicine Part 2: Pain

      11 October 2019 Open Access Government
    • Cannabinoids in medicine Part 1: Cancer

      22 August 2019 Open Access Government
    • An interview with Neil Mahapatra

      08 January 2019 The Times Magazine
    • High life: the start-up hoping to unlock the secrets of medical cannabis

      09 August 2018 Evening Standard
    • Oxford Cannabinoid Technologoies goes global as it announces close of series a fundraising round and management team line-up

      28 June 2018 OCT Press Release
    • Embracing the medical potential of cannabinoids

      01 June 2017 The Medicine Maker
    • Smashing the stigma with science

      01 June 2017 The Medicine Maker
    • Oxford University launches £10m research project into medical marijuana

      16 March 2017 Evening Standard
    • Oxford University to launch study on medical benefits of marijuana

      16 March 2017 The Telegraph
    • Oxford University to launch multimillion-dollar medical marijuana research program

      16 March 2017 CNBC
    • Oxford University launches £10m marijuana research programme

      16 March 2017 BBC
    • The University of Oxford and Kingsley Capital Partners announce ground breaking Cannabinoid Biomedicine Research Programme

      15 March 2017 OCT Press Release